CD8A and neoplasm: Because our data show that BVax can continue to activate CD8+ T cells in-vivo, we envision a dual role for both BVax and DC vaccines where BVax serves to maintain a pool of anti-tumor stem-like T cells, and DC vaccines rapidly generate effector cytotoxic T cells to kill the primary tumor or any recurrence.